治疗前[18F]FDG PET/CT全脑代谢活动提供超越肿瘤代谢负荷的乳腺癌预后信息
该单中心回顾性队列纳入358例活检确诊乳腺癌患者,治疗前接受[18F]FDG PET/CT分期,测量全脑SUVmean、SULmean及全身肿瘤代谢体积(TMTV)。校正年龄、BMI、病变范围、空腹血糖和TMTV后,全脑SUVmean仍独立与总生存相关(HR 0.810,95%CI 0.679-0.967,P=0.019),提示全脑代谢活动可提供超越全局肿瘤代谢负荷的预后信息。
要点
- 全脑SUVmean升高与更好总生存独立相关(校正后HR 0.810,P=0.019)。
- TMTV校正后仍保留预后价值(HR 1.104,P<0.001)。
- TMTV/全脑SUVmean联合分层可区分三个预后组(全局log-rank P=2.14×10⁻¹⁰)。
核心结论
- 治疗前全脑代谢活动可提供超越全局肿瘤代谢负荷的乳腺癌预后信息,可能代表互补的宿主相关预后信号,但生物学机制需进一步验证。
研究设计与样本
- 单中心回顾性队列纳入358例活检确诊乳腺癌患者,治疗前接受[18F]FDG PET/CT分期,采用半自动工作流测量全脑SUVmean、SULmean和TMTV,主要终点为总生存。
主要发现
- 单变量分析中,较高TMTV与更差总生存相关(每100 mL HR 1.167,P<0.001)。
- 单变量分析中,较高全脑SUVmean(HR 0.785,P<0.001)和全脑SULmean(HR 0.733,P<0.001)与更好总生存相关。
- 校正年龄、BMI、病变范围、空腹血糖和TMTV后,全脑SUVmean仍独立与总生存相关(HR 0.810,95%CI 0.679-0.967,P=0.019),TMTV保留预后价值(HR 1.104,95%CI 1.053-1.157,P<0.001)。
- 敏感性分析中全脑SULmean结果相似(HR 0.764,95%CI 0.586-0.997,P=0.047)。
- TMTV/全脑SUVmean联合分层识别三个预后组(全局log-rank P=2.14×10⁻¹⁰)。
临床怎么用
- 乳腺癌患者治疗前[18F]FDG PET/CT除评估肿瘤代谢负荷外,可考虑测量全脑代谢活动以补充预后分层信息。
局限性
- 单中心回顾性设计,结论需外部验证。
- 全脑代谢活动作为宿主相关预后信号的生物学机制尚不清楚,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate whether whole-brain (WB) metabolic activity measured on pretreatment [18 F]FDG PET/CT provides prognostic information beyond global metabolic tumour burden in patients with breast cancer. METHODS: This single-centre retrospective cohort included 358 patients with biopsy-confirmed breast cancer who underwent pretreatment [18 F]FDG PET/CT for staging. WB SUVmean, WB SULmean, and total metabolic tumour volume (TMTV) were measured using a semi-automated PET/CT analysis workflow. The primary endpoint was overall survival (OS). Sequential Cox models evaluated the incremental prognostic value of WB SUVmean beyond clinical variables and TMTV; WB SULmean was assessed in sensitivity analysis. RESULTS: Complete-case data were available for 354 patients. In univariable analysis, higher TMTV was associated with worse OS (HR 1.167 per 100 mL; P < 0.001), whereas higher WB SUVmean (HR 0.785; P < 0.001) and WB SULmean (HR 0.733; P < 0.001) were associated with better OS. After adjustment for age, body mass index, disease extent, fasting glucose, and TMTV, WB SUVmean remained independently associated with OS (HR 0.810, 95% CI 0.679-0.967; P = 0.019), while TMTV retained prognostic value (HR 1.104, 95% CI 1.053-1.157; P < 0.001). WB SULmean showed similar results in sensitivity analysis (HR 0.764, 95% CI 0.586-0.997; P = 0.047). Combined TMTV/WB SUVmean stratification identified three prognostic groups (global log-rank P = 2.14 × 10⁻¹⁰). CONCLUSION: Pretreatment WB metabolic activity provides prognostic information beyond global metabolic tumour burden in breast cancer and may represent a complementary host-related prognostic signal, although the underlying biological mechanisms require further validation.
引用
- Tatoğlu MT, Canıtez B, Uslu H, et al. Whole-brain metabolic activity on pretreatment [18 F]FDG PET/CT provides prognostic information beyond metabolic tumour burden in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42384205. doi:10.1007/s00259-026-08046-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。